UBS Group’s Psyence Biomedical PBM Stock Holding History

UBS Group’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184	Buy	+60	New	+$273	﹤0.01%	10017
2026 Q1	–	Sell	-161	Closed	-$758	–	11284
2025 Q4	$758	Buy	+161	New	+$2.4K	﹤0.01%	9824
2025 Q3	–	Sell	-313	Closed	-$10.4K	–	11046
2025 Q2	$10.4K	Sell	313 -361	-54%	-$9.99K	﹤0.01%	8840
2025 Q1	$20.1K	Buy	674 +419	+164%	+$26.7K	﹤0.01%	8236
2024 Q4	$26.8K	Buy	255 +251	+6,275%	+$59.8K	﹤0.01%	7686
2024 Q3	$1.5K	Sell	4 -2	-33%	-$2.71K	﹤0.01%	8621
2024 Q2	$6.87K	Buy	6 +5	+500%	+$15K	﹤0.01%	7882
2024 Q1	$2.69K	Buy	+1	New	+$4.17K	﹤0.01%	7846

Other funds holding PBM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.93B AUM 16.26% 1-Year Est. Return

Caitlin John Brighton, Michigan $183M AUM 30.77% 1-Year Est. Return

UBS Group's PBM Position: Q2 2026 in Review

UBS Group opened a new position in Psyence Biomedical (PBM) in Q2 2026: 60 shares worth $184. The stake represents ﹤0.01% of the portfolio and ranks #10017 among its holdings. This is a return to the name: UBS Group previously reported a position in PBM as recently as Q4 2025.

UBS Group first reported a position in PBM in Q1 2024 and has held it in 8 quarters since. The position peaked at $26.8K in Q4 2024. 9 funds tracked by Wall St. Rank hold PBM as of Q2 2026.

UBS Group held 60 shares of Psyence Biomedical worth $184 as of Q2 2026.
Psyence Biomedical was a new UBS Group position in Q2 2026.
Psyence Biomedical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10017 holding.
UBS Group first reported a position in Psyence Biomedical in Q1 2024 and has held it in 8 quarters since.
UBS Group's Psyence Biomedical position peaked at $26.8K in Q4 2024.
9 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.